Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAU-SED vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Mild to moderate hypertension,Management of psychotic disorders (off-label)
Hypertension
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Extensively metabolized in the liver via ester hydrolysis; major metabolite is trimethoxybenzoic acid; not fully characterized in humans.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
96% bound, primarily to albumin and alpha-1-acid glycoprotein
~90%, primarily to albumin
8-10 L/kg; clinical meaning: extensive tissue distribution, high affinity for adipose tissue and brain
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 40-50% (first-pass metabolism); Intramuscular: 100% (complete absorption)
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce dose by 50%. No adjustment needed for Cr Cl >60 m L/min.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For moderate impairment (Child-Pugh Class B), reduce dose by 50% and monitor for excessive sedation. No adjustment for mild (Child-Pugh Class A).
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended due to lack of safety and efficacy data. Avoid use in children.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate with 0.1 mg orally once daily; titrate slowly based on response and tolerability. Monitor for orthostatic hypotension and sedation.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Reserpine may increase the risk of suicide; patients should be monitored for depression. It should not be used in patients with a history of mental depression.
None
May cause severe depression, especially in patients with psychiatric history; may cause bradycardia, electrolyte imbalance, and gastrointestinal effects; caution in patients with peptic ulcer disease or gallstones due to increased gastric acid secretion.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
History of mental depression (especially suicidal tendencies), active peptic ulcer, ulcerative colitis, concurrent electroconvulsive therapy (ECT), hypersensitivity to reserpine or rauwolfia alkaloids.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce) as rauwolfia alkaloids can potentiate hypertensive crises. Limit caffeine intake. High-fiber diets may reduce absorption separate doses.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered elevated. Second/third trimesters: Risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use throughout pregnancy unless essential.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk. M/P ratio not reported. Potential for infant effects: nasal congestion, bradycardia, hypotonia. Use is contraindicated due to possible severe adverse effects in the nursing infant.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Dose should be kept as low as possible. Due to increased plasma volume in pregnancy, monitor clinical response; no specific dose adjustment recommendations. Consider alternative antihypertensives with better safety profile.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
RAU-SED (rauwolfia serpentina) is an antihypertensive and antipsychotic alkaloid. Onset of action is slow (2-3 weeks) for hypertension. Monitor for bradycardia, nasal congestion, and depression. Do not use with MAOIs or electroconvulsive therapy. Taper to avoid withdrawal hypertension.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop suddenly as this may cause severe hypertension.,May cause drowsiness, dizziness, or nasal congestion; avoid driving if affected.,Report signs of depression, nightmares, or extrapyramidal symptoms (muscle stiffness, tremors).,Avoid alcohol and over-the-counter cold medications containing decongestants.,Rise slowly from sitting or lying to minimize postural hypotension.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAU-SED vs ALDORIL 15, answered by our medical review team.
RAU-SED is a Antihypertensive that works by Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAU-SED and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAU-SED is: Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAU-SED and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAU-SED is classified as Category C. Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered e. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.